|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Exclusive News
3 Dividend Aristocrats Whose Yields Can Help Combat InflationAuthor: Chris Markoch. First Published: 4/9/2026. 
Key Points
- Dividend Aristocrats including Amcor, Chevron, and AbbVie can provide reliable income streams that can help offset persistent inflation.
- Each of those three companies offers a yield above 3% combined with decades of consistent dividend growth, signaling strong financial stability.
- These stocks also provide exposure to defensive sectors like packaging, energy, and health care, which tend to perform well during periods of elevated inflation.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
The calendar says it’s spring, but investors may feel like it’s Groundhog Day: the economic issues affecting portfolios continue to persist. After a ceasefire between the United States and Iran briefly provided a market tailwind, fresh inflation readings suggest inflation may be creeping back. The Personal Consumption Expenditures (PCE) index reading and the Consumer Price Index (CPI) for March are both due this week, and both reports are expected to show inflation rising again. Markets are watching closely.
Wall St. Insider Warns: This Could Leapfrog Elon's SpaceX IPO
Elon Musk could take SpaceX public in 2026, at an estimated $1.75 trillion valuation. The IPO would include Elon's AI model, Grok. But according to Louis Navellier, a radical new AI model will launch this year… over 1,000 times more powerful than Elon's. And the company behind it could outperform SpaceX in the process. Click here for full details (including Louis' new pick — free).
Worryingly, the inflation data so far doesn’t fully reflect the impact of higher oil prices, which tend to be inflationary. Whether that effect proves to be a short-term headwind or a longer-term challenge remains to be seen. There are many layers to the inflation story. Even if oil prices fall and the economy accelerates, stronger demand can be inflationary. Interest rates matter, too: the Federal Reserve has paused rate cuts, and a vocal group of market participants now thinks the next directional move for rates could be higher. One near-term certainty is that inflation is unlikely to fall to the Fed’s 2% target anytime soon. A practical move for investors right now is to consider dividend stocks yielding more than 3%. Even if share prices stagnate, growing yields can help returns stay ahead of inflation. Rather than chasing the highest yields, look for companies with histories of consistently paying and reliably growing dividends. The following three Dividend Aristocrats have increased payouts for at least 25 consecutive years and deserve a closer look. Amcor Offers High Yield With Defensive DemandAmcor (NYSE: AMCR) is a global packaging company with market leadership across food and beverage, pharmaceutical and personal care categories. Its products benefit from steady demand, particularly when companies seek ways to trim input costs. AMCR’s share price has been mostly flat over the past 12 months, which hasn’t excited investors. However, its dividend appears secure. The company has increased its payout for 27 consecutive years, a streak that incorporates dividend history from its 2019 Bemis acquisition. As of April 9, the yield was 6.3%, with an annual payout of $2.60 per share. Amcor faces cost pressures from tariffs and higher oil prices, and at roughly 27x earnings AMCR looks expensive relative to its history and the broader market. Still, the dividend is intact, and analysts maintain a consensus one-year price target of $52, which would imply more than 20% upside in addition to a sizable yield. Chevron Combines Energy Exposure With Dividend StrengthEnergy stocks have been volatile since the Iran conflict began in late February. Chevron (NYSE: CVX) has been one of the beneficiaries — year to date, CVX is up almost 30%. If oil stays elevated, holders will be rewarded; if prices retreat, Chevron’s scale still supports a strong long-term case. Even if oil weaken, Chevron remains a best-in-class integrated major that is expanding output in the United States and, more recently, in Venezuela. The company also has meaningful exposure to the growing liquefied natural gas market and strategic investments in renewable energy. The recent rally has pushed CVX’s valuation higher, but owning Chevron is a long-term decision. Over time the company has been a good steward of capital: in 2025 it generated $20.2 billion in free cash flow and returned a record $27 billion to shareholders via dividends and buybacks. Chevron’s dividend yields about 3.6%, equivalent to $7.12 per share annually, and the company has increased its payout for 38 consecutive years. AbbVie Delivers Reliable Growth and Income in Health CareHealth care isn’t the first sector investors think of for inflation protection, but prescription demand is relatively inelastic — people don’t stop taking medicines when prices rise. That durability makes AbbVie (NYSE: ABBV) worth considering. For fiscal 2025, AbbVie reported record revenue of $61.2 billion, with immunology sales up 14% driven by Skyrizi and Rinvoq. Those drugs have helped replace revenue lost after Humira’s patent expiration. That performance matters for the dividend story. Despite concerns that Humira’s patent loss could pressure payouts, ABBV has continued to raise its dividend and now boasts a streak of 52 consecutive years of increases. The yield is about 3.3%, or $6.92 per share annually. AbbVie is a stock to own for the long term and let compounding work. |
Post a Comment
Post a Comment